$55.27
0.20 (-0.36%)
Last updated: Apr 16, 2026 00:49
Fundamentals Overview
BioMarin Pharmaceutical Inc. is in the middle of its 52-week range with premium valuation, trading relatively flat today.
Valuation premium
Intrinsic value (DCF)
-80% downside vs price
Profitability
Risk (Beta)
0.29 — lower vol
Earnings & growth
BullzEye Analysis
Our composite tilts Hold on technicals (e.g. RSI, ADX, trend), fundamentals, sentiment, sector and index context, and risk.
Composite Signal
Supporting (Buy):
Analyst grade: A-
Pressures (Sell):
DCF 80% downside vs price · Sentiment weakening (2 downgrades)
Not financial advice. For education and research only; do your own research and consider a financial advisor before investing.
Key Stats
About
Ratings & Grades at a Glance
Overall rating: A-. Recent institutional grades: majority downgrades. Current institutional positions: Buy: 12, Hold: 1, Market Perform: 1, Neutral: 4, Outperform: 3, Overweight: 9.
Valuation & Ratios
Valuation, liquidity, and profitability metrics are consolidated here (including ratios that previously appeared in the Financials story). Trailing (TTM) vs forward-looking (e.g. DCF) is noted on each line where it matters.
DCF vs price: DCF estimate is $11.03; current price is $55.27. That’s a -80% gap. When the gap is large (e.g. >20%), that’s divergence; when they’re close, that’s convergence. Differences can reflect growth expectations, sector premiums, or conservative vs. optimistic assumptions. Use DCF as one input alongside technicals and sentiment.
| Metric | Value |
|---|---|
| Valuation | |
| P/E (TTM) | 31.27 |
| DCF value (model) | $11.03 (-80% vs price) |
| PEG (TTM) | N/A |
| P/B (TTM) | 1.74 |
| P/S (TTM) | 3.3 |
| P/FCF (TTM) | 14.66 |
| Liquidity & enterprise | |
| Current Ratio (TTM) | 5.21 |
| Quick Ratio (TTM) | 3.5 |
| Cash Ratio (TTM) | 1.73 |
| Profitability | |
| ROE (TTM) | N/A |
| ROA (TTM) | N/A |
| Revenue growth (YoY) | N/A |
| Net margin (TTM) | 10.83% |
| Gross margin (TTM) | 77.13% |
| Operating margin (TTM) | 16.56% |
| Debt to equity (TTM) | N/A |
Latest News
News loads when you open this tab.
Price Target, Ratings & Grades
Analyst price targets, consensus, rating snapshot, and institutional grades for BMRN.
Analyst Sentiment at a Glance
Stock Grades (Institutions)
| Institution | Action | Previous Grade | New Grade | Date |
|---|---|---|---|---|
| B of A Securities | maintain | Buy | Buy | 2026-03-11 |
| Barclays | maintain | Overweight | Overweight | 2026-03-04 |
| Freedom Broker | maintain | Buy | Buy | 2026-03-02 |
| HC Wainwright & Co. | maintain | Neutral | Neutral | 2026-03-02 |
| Canaccord Genuity | maintain | Buy | Buy | 2026-02-26 |
| Bernstein | maintain | Outperform | Outperform | 2026-02-25 |
| Guggenheim | maintain | Buy | Buy | 2026-02-25 |
| HC Wainwright & Co. | maintain | Neutral | Neutral | 2026-02-25 |
| Oppenheimer | maintain | Outperform | Outperform | 2026-02-24 |
| Wells Fargo | maintain | Overweight | Overweight | 2026-02-18 |
| Piper Sandler | maintain | Overweight | Overweight | 2026-02-06 |
| Canaccord Genuity | upgrade | Hold | Buy | 2026-01-20 |
| Truist Securities | maintain | Buy | Buy | 2025-12-23 |
| HC Wainwright & Co. | maintain | Neutral | Neutral | 2025-12-22 |
| Leerink Partners | downgrade | Outperform | Market Perform | 2025-12-03 |
| Stifel | downgrade | Buy | Hold | 2025-11-06 |
| Freedom Broker | maintain | Buy | Buy | 2025-11-03 |
| Bernstein | maintain | Outperform | Outperform | 2025-11-03 |
| Wells Fargo | maintain | Overweight | Overweight | 2025-10-28 |
| Barclays | maintain | Overweight | Overweight | 2025-10-28 |
| Morgan Stanley | maintain | Overweight | Overweight | 2025-10-28 |
| Truist Securities | maintain | Buy | Buy | 2025-10-28 |
| Stifel | maintain | Buy | Buy | 2025-10-28 |
| HC Wainwright & Co. | maintain | Neutral | Neutral | 2025-10-27 |
| JP Morgan | maintain | Overweight | Overweight | 2025-10-09 |
| Guggenheim | maintain | Buy | Buy | 2025-08-06 |
| UBS | maintain | Buy | Buy | 2025-08-05 |
| Morgan Stanley | maintain | Overweight | Overweight | 2025-07-22 |
| JP Morgan | maintain | Overweight | Overweight | 2025-07-14 |
| Goldman Sachs | maintain | Buy | Buy | 2025-05-05 |